Susan J Ramus

List of Publications by Citations

Source: https://exaly.com/author-pdf/7183838/susan-j-ramus-publications-by-citations.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 papers	13,033 citations	60 h-index	106 g-index
244 ext. papers	15,342 ext. citations	8.1 avg, IF	4.8 L-index

#	Paper	IF	Citations
228	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Research*, **2010**, 20, 440-6	9.7	638
227	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
226	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA - Journal of the American Medical Association*, **2012**, 307, 382-90	27.4	427
225	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
224	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
223	Multiple loci with different cancer specificities within the 8q24 gene desert. *Journal of the National Cancer Institute*, **2008**, 100, 962-6	9.7	283
222	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nature Genetics*, **2010**, 42, 874-9	36.3	277
221	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
220	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
219	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
218	An epigenetic signature in peripheral blood predicts active ovarian cancer. *PLoS ONE*, **2009**, 4, e8274	3.7	245
217	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nature Genetics*, **2009**, 41, 996-1000	36.3	240
216	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	239
215	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
214	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
213	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. *Journal of Clinical Oncology*, **2015**, 33, 2901-7	2.2	200
212	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190

211	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
210	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
209	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
208	Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the National Cancer Institute*, **2014**, 106, djt431	9.7	149
207	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
206	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
205	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, **2013**, 20, 251-62	5.7	135
204	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
203	The contribution of BRCA1 and BRCA2 to ovarian cancer. *Molecular Oncology*, **2009**, 3, 138-50	7.9	125
202	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
201	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. *International Journal of Gynecological Pathology*, **2016**, 35, 430-41	3.2	121
200	Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. *British Journal of Cancer*, **2004**, 91, 1911-5	8.7	119
199	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
198	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
197	Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. *Journal of Pathology*, **2007**, 211, 286-95	9.4	94
196	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. *Journal of the National Cancer Institute*, **2018**, 110, 714-725	9.7	92
195	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1156-66	4	92
194	Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. *Oncogene*, **2004**, 23, 5697-702	9.2	92

193	The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Human Molecular Genetics*, **2014**, 23, 4703-9	5.6	90
192	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
191	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. *Clinical Cancer Research*, **2008**, 14, 3761-7	12.9	77
190	Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. *International Journal of Cancer*, **2000**, 87, 317-21	7.5	77
189	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630	7.8	77
188	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
187	Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2007**, 67, 3027-35	10.1	75
186	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
185	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. *Lancet Oncology, The*, **2013**, 14, 1226-32	21.7	73
184	Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. *Human Pathology*, **2000**, 31, 1420-1424	3.7	71
183	LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Research*, **2011**, 71, 3896-903	10.1	70
182	Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. *Breast Cancer Research*, **2009**, 11, R80	8.3	70
181	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes and Control*, **2013**, 24, 989-1004	2.8	69
180	Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. *Clinical and Experimental Metastasis*, **2004**, 21, 543-52	4.7	68
179	Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. *International Journal of Gynecological Pathology*, **2004**, 23, 29-34	3.2	68
178	Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. *Human Mutation*, **2007**, 28, 1207-15	4.7	67
177	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
176	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65

175	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 245-50	4	64
174	Common variants in mismatch repair genes and risk of invasive ovarian cancer. *Carcinogenesis*, **2006**, 27, 2235-42	4.6	64
173	Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. *Genes Chromosomes and Cancer*, **1999**, 25, 91-6	5	64
172	Efficient molecular subtype classification of high-grade serous ovarian cancer. *Journal of Pathology*, **2015**, 236, 272-7	9.4	63
171	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
170	Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nature Genetics*, **2015**, 47, 888-97	36.3	60
169	Role of genetic polymorphisms and ovarian cancer susceptibility. *Molecular Oncology*, **2009**, 3, 171-81	7.9	59
168	Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2557-65	4	58
167	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
166	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
165	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
164	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
163	The clonal evolution of metastases from primary serous epithelial ovarian cancers. *International Journal of Cancer*, **2009**, 124, 1579-86	7.5	53
162	Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2009**, 69, 2349-57	10.1	52
161	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
160	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. *Clinical Cancer Research*, **2017**, 23, 1552-1563	12.9	49
159	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *British Journal of Cancer*, **2014**, 111, 2297-307	8.7	49
158	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. *International Journal of Cancer*, **2011**, 128, 2063-74	7.5	49

157	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48
156	Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. *PLoS ONE*, **2007**, 2, e268	3.7	47
155	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
154	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
153	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
152	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
151	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. *International Journal of Cancer*, **2011**, 128, 936-43	7.5	44
150	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
149	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, **2010**, 6, e1001016	6	42
148	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2009**, 100, 412-20	8.7	42
147	Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. *British Journal of Cancer*, **2008**, 98, 282-8	8.7	42
146	Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. *PLoS ONE*, **2011**, 6, e24987	3.7	41
145	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
144	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
143	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 880-90	4	37
142	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. *Human Molecular Genetics*, **2009**, 18, 2297-304	5.6	37
141	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
140	Risk of ovarian cancer and the NF-B pathway: genetic association with IL1A and TNFSF10. *Cancer Research*, **2014**, 74, 852-61	10.1	36

139	Morphological predictors of BRCA1 germline mutations in young women with breast cancer. *British Journal of Cancer*, **2011**, 104, 903-9	8.7	35
138	Ovarian cancer risk associated with inherited inflammation-related variants. *Cancer Research*, **2012**, 72, 1064-9	10.1	35
137	PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	34
136	Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. *British Journal of Cancer*, **2009**, 101, 1461-8	8.7	34
135	Common variants in RB1 gene and risk of invasive ovarian cancer. *Cancer Research*, **2006**, 66, 10220-6	10.1	34
134	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
133	Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. *Clinical Cancer Research*, **2008**, 14, 5840-8	12.9	33
132	Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. *Cancer Genetics and Cytogenetics*, **2005**, 160, 134-40		33
131	Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. *European Journal of Surgical Oncology*, **2001**, 27, 278-81	3.6	33
130	Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. *PLoS ONE*, **2009**, 4, e5983	3.7	33
129	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
128	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
127	Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. *Neoplasia*, **2010**, 12, 579-89	6.4	32
126	Complete mutation detection using unlabeled chemical cleavage. *Human Mutation*, **1992**, 1, 63-9	4.7	32
125	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
124	Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 935-44	4	31
123	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30
122	The effects of common genetic variants in oncogenes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 5833-9	12.9	30

121	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget*, **2017**, 8, 50930-50940	3.3	30
120	Telomere structure and maintenance gene variants and risk of five cancer types. *International Journal of Cancer*, **2016**, 139, 2655-2670	7.5	30
119	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *Journal of Medical Genetics*, **2018**, 55, 546-554	5.8	30
118	BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. *Cancer Research*, **2003**, 63, 417-23	10.1	30
117	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
116	ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2012**, 23, 1805-10	2.8	27
115	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. *Journal of Clinical Epidemiology*, **2011**, 64, 525-30	5.7	27
114	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26
113	Simultaneous screening for beta-thalassemia mutations by chemical cleavage of mismatch. *Genomics*, **1991**, 11, 48-53	4.3	26
112	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 395-404	4	25
111	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
110	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. *Gynecologic Oncology*, **2010**, 119, 479-83	4.9	25
109	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
108	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
107	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
106	Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 1090-5	12.9	24
105	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstetrics and Gynecology*, **2016**, 127, 828-836	4.9	24
104	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1822-30	4	22

103	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
102	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
101	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
100	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. *Clinical Cancer Research*, **2019**, 25, 5937-5946	12.9	21
99	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
98	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Human Genetics*, **2014**, 133, 481-97	6.3	21
97	Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. *British Journal of Cancer*, **2009**, 100, 993-1001	8.7	21
96	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
95	Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, **2014**, 2, 332-40	12.5	20
94	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 987-92	4	20
93	Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 600-4	4	20
92	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
91	Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. *European Journal of Cancer*, **2008**, 44, 2259-65	7.5	20
90	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e20703	3.7	20
89	Inherited variants in regulatory T cell genes and outcome of ovarian cancer. *PLoS ONE*, **2013**, 8, e53903	3.7	19
88	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
87	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18
86	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18

85	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertility and Sterility*, **2011**, 95, 40-5	4.8	18
84	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. *Human Molecular Genetics*, **2011**, 20, 2263-72	5.6	18
83	MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1793-7	4	18
82	BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. *European Journal of Cancer*, **2007**, 43, 823-7	7.5	18
81	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
80	Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer*, **2019**, 19, 339-348	31.3	17
79	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
78	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
77	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
76	A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. *BMC Cancer*, **2011**, 11, 119	4.8	16
75	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. *Human Molecular Genetics*, **2009**, 18, 1869-78	5.6	16
74	Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria. *Human Mutation*, **1992**, 1, 154-8	4.7	16
73	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
72	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
71	Genotype and intellectual phenotype in untreated phenylketonuria patients. *Pediatric Research*, **1999**, 45, 474-81	3.2	15
70	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
69	Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 3567-72	4	14
68	LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. *Clinical and Experimental Metastasis*, **2004**, 21, 535-41	4.7	14

67	Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. *International Journal of Gynecological Pathology*, **2000**, 19, 390-4	3.2	14
66	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
65	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. *Molecular Cancer Therapeutics*, **2015**, 14, 1495-503	6.1	13
64	Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2123-31	4	13
63	Risk of ovarian cancer in women with first-degree relatives with cancer. *Acta Obstetricia Et Gynecologica Scandinavica*, **2009**, 88, 449-56	3.8	13
62	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
61	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
60	Idiopathic slow-transit constipation is not associated with mutations of the RET proto-oncogene or GDNF. *Diseases of the Colon and Rectum*, **2000**, 43, 851-7	3.1	12
59	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. *PLoS ONE*, **2016**, 11, e0153844	3.7	12
58	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
57	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11
56	Variation in NF-B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1421-7	4	11
55	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
54	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. *Cancer Research*, **2019**, 79, 467-481	10.1	11
53	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
52	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. *International Journal of Cancer*, **2009**, 124, 1037-44	7.5	10
51	Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. *Cancer Research*, **2008**, 68, 8837-42	10.1	10
50	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. *Gynecologic Oncology*, **2018**, 150, 527-533	4.9	9

49	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
48	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. *Breast Cancer Research*, **2011**, 13, R14	8.3	9
47	A spontaneous mutation causing unstable Hb Hammersmith: detection of the beta 42 TTT----TCT change by CCM and direct sequencing. *British Journal of Haematology*, **1991**, 79, 127-9	4.5	9
46	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
45	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2018**, 47, 450-459	7.8	8
44	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
43	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Molecular Nutrition and Food Research*, **2014**, 58, 2023-35	5.9	8
42	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
41	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. *Twin Research and Human Genetics*, **2012**, 15, 615-623	2.2	8
40	Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online. *Human Mutation*, **2007**, 28, 525-6	4.7	8
39	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
38	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
37	Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer. *Oncology*, **2016**, 90, 59-68	3.6	7
36	Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 529-36	4	7
35	Phenotype-directed analysis of genotype in early-onset, familial breast cancers. *Pathology*, **2006**, 38, 520-7	1.6	7
34	Cancer Risks Associated With and Pathogenic Variants.. *Journal of Clinical Oncology*, **2022**, JCO2102112	2.2	7
33	A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. *International Journal of Molecular Epidemiology and Genetics*, **2010**, 1, 272-7	0.9	7
32	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7

31	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *International Journal of Cancer*, **2016**, 139, 2646-2654	7.5	6
30	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
29	Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers. *Pathology*, **2012**, 44, 89-98	1.6	6
28	Single-tube chemical cleavage of mismatch: successive treatment with hydroxylamine and osmium tetroxide. *BioTechniques*, **1996**, 21, 216-8, 220	2.5	6
27	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
26	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 116-125	4	5
25	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
24	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. *Journal of Medical Genetics*, **2021**,	5.8	5
23	Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. *Cancers*, **2020**, 12,	6.6	5
22	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
21	Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e19642	3.7	4
20	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
19	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
18	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
17	CpG hotspot causes second mutation in codon 408 of the phenylalanine hydroxylase gene. *Human Genetics*, **1992**, 90, 147-8	6.3	3
16	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
15	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. *Journal of the National Cancer Institute*, **2021**, 113, 301-308	9.7	3
14	Mutations Ivs4nt1, 47delCT, and G148S identified in the phenylalanine hydroxylase gene by RT-PCR of illegitimate transcripts and chemical cleavage of mismatch. *Human Mutation*, **1995**, 6, 250-1	4.7	2

13	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
12	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors		2
11	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2
10	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2
9	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
8	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. *European Journal of Epidemiology*, **2020**, 35, 1025-1042	12.1	2
7	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	2
6	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
5	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. *British Journal of Cancer*, **2021**, 125, 265-276	8.7	1
4	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1
3	Somatic Genetic Development in Epithelial Ovarian Cancer **2009**, 215-246		1
2	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1028-31	4	
1	Polymorphism in the 3Ountranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. *Human Genetics*, **1995**, 96, 741-3	6.3	